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Islet Transplantation a Decade Later and Strategies for
Filling a Half-Full Glass
R. Paul Robertson
Alloislet transplantation for the treatment of type 1 diabe-
tes enjoyed highly favorable status in the ﬁrst half of the
last decade but declined in favor during the second half. In
this Perspective, I will brieﬂy review the literature pub-
lished in this area from 2000 to 2010 for the purposes of
extracting lessons we have learned, considering whether
the procedure should be deemed a partial success or a
partial failure, and offering several strategies to improve
alloislet transplantation outcomes in the future. In the
end, I hope to strike a positive note about where this
procedure is going, and how it will be applied to establish
insulin independence in patients with type 1 diabetes.
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uccessful pancreatic islet transplantation was es-
tablished using rodents in 1972 and became a
reality for humans in 1980. The application of this
technology to patients with type 1 diabetes
proved to be difﬁcult and, for various reasons, lagged as a
successful procedure until 2000. That year, the seminal
publication by Shapiro et al. (1) from the University of
Alberta, Edmonton, appeared and caused a huge wave of
excitement and optimism about a cure for type 1 diabetes.
A solution to insulin-induced hypoglycemia, perhaps the
most vexing complication to insulin-based therapy, ap-
peared to be at hand. Now, a decade later, a more
circumspect attitude of reﬂection and retooling pervades
the picture. This is an archetypical scenario for research
ﬁndings that make a big splash in the scientiﬁc and lay
press. Nonetheless, the facts remain. Seven consecutive
type 1 diabetic patients were rendered insulin independent
and free of hypoglycemia by islet transplantation, a re-
markable accomplishment that spawned many research
programs world-wide focused on curing diabetes with this
procedure.
In this Perspective I will brieﬂy review the recent history
of successful islet transplantation and point out some of
the lessons we have learned from this intensive experi-
ence. This will be followed by a consideration of whether
this technology is more success or failure. The ﬁnal
section will look to the future, i.e., how do we apply the
lessons we have learned to modify islet transplantation so
that it will come closer to the expectations it elicited in
2000?
Lessons learned. The consensus father of islet transplan-
tation is Paul Lacy. His vision, leadership, and hard work
established the procedure of using the liver as a site for
successful islet transplantation. The transplants normal-
ized glycemia in rats previously made diabetic by strepto-
zotocin injection (2). As he and his colleagues began
publishing manuscripts, it did not take long for the surgi-
cal community to apply this technique to humans (Fig. 1)
(3). This proved to be a much more ambitious task than
ﬁrst imagined. Transporting pancreata isolated from brain-
dead donors on life support, the inherent delays in islet
isolation, the presence of autoimmune disease in the
recipients, and the need to use powerful immunosuppres-
sive drugs with signiﬁcant side effects all presented signif-
icant barriers.
Najarian and Sutherland at the University of Minne-
sota transplanted islets in nondiabetic recipients who
were their own donors and reported reproducible suc-
cesses beginning in 1980 (4). The patients had various
forms of chronic, unrelentingly painful pancreatitis and
each underwent a total pancreatectomy for pain relief
and nutritional rehabilitation. Rather than dispose of the
patient’s resected pancreas, the clinical researchers
used it to make a crude extract of islets that was
returned to the operating room within 2 h. The islets
were infused over 30 min into the patient’s liver
while hepatic portal venous pressure was monitored. A
summary of the results reported that if over 300,000
autoislets could be transplanted, the success rate of
preventing diabetes for more than 2 years was 74% (5).
Nonetheless, the ﬁrst reproducible successes with allo-
grafts were not reported until 2000.
The autoislet experience was very encouraging because
it proved that islet transplantation in nondiabetic humans
was feasible. The stage for future successes in alloislet
transplantation in patients with type 1 diabetes was set.
Case reports and small patient series’ revealed evidence
for function of islets after transplantation and brief or
partial improvement in glycemic control (6–11). One vex-
ing variable was the irony that one of the drugs important
generally for transplantation success, cyclosporine, had
inhibitory effects on -cell function (12–19). Oddly, this
became the pattern for other important immunosuppres-
sive drugs (3), especially glucocorticoids (14,18,20–22).
This led to the use of a glucocorticoid-free immunosup-
pressive regimen developed by Shapiro et al. (1), which in
turn led to their now historic series of successful islet
transplants in type 1 diabetic patients. Another key aspect
of the Edmonton approach was to use an average of two
sequential islet transplants to establish normoglycemia.
Over time, however, the successes enjoyed by the
Edmonton group began to slowly diminish. In the year
2000, the ﬁrst seven patients who were insulin free had
normal or nearly normal levels of glucose and A1C. Over 2
years the series had grown to 17 patients, 14 (86%) of
whom were C-peptide positive and 11 of whom remained
insulin free, although two were using oral hypoglycemic
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patients, 85% of whom were C-peptide positive but only
15% of whom were insulin-free (24). The other 85%, who
were again using insulin, were reported to be using less
than they had been pretransplantation. Using these data,
the median time to a return to insulin therapy was calcu-
lated to be 15 months.
Meanwhile, the Immune Tolerance Network (ITN) had
undertaken a multicenter trial of alloislet intrahepatic
transplantation using the Edmonton protocol. The goal
was to establish the ﬁdelity with which nine centers in
Canada, the U.S., and Europe could reproduce the initial
Edmonton results. This consortium reported in 2006 (25)
that, of 36 type 1 diabetic subjects studied, 44% achieved
the primary end point of insulin independence with ade-
quate glycemic control 1 year after islet transplantation. It
is noteworthy that previous experience with islet trans-
plantation at the various research sites was strongly
associated with success in achieving the primary end
points. Of the 18 subjects, 12 (67%) were successful at 1
year post-transplant at sites where 4 or more patients had
been transplanted in the preceding 2 years. Only 4 of 18
subjects (22%) were successful at sites where there was a
history of less than four transplantations previously. This
outcome clearly signaled that the procedure itself has a
steep learning curve. At this time, it remains more of a
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FIG. 1. General method of intrahepatic islet transplantation. Islets are removed from a donated pancreas by collagenase digestion, followed by
puriﬁcation to separate the islets from exocrine tissue. Islets are then infused by gravity into a catheter lodged in the hepatic portal vein. Blood
ﬂow within the vein carries the islets into the liver tributaries where they lodge within the sinusoids and establish vascular connections.
Reproduced with permission from ref. 3.
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treating patients with type 1 diabetes.
During the past decade other groups reported results
that were generally in agreement with the Edmonton and
ITN outcomes. As early as 2000, Oberholzer et al. (11)
reported that of 13 of 13 alloislet recipients had measure-
able blood C-peptide levels for at least 3 months, as did 7
of 11 recipients at 6 months and 5 of 8 recipients at 1 year
post-transplant. Froud et al. (26) used the Edmonton
protocol and reported success rates of 79% for insulin
independence at 1 year and 43% at 18 months for 16
recipients. Toso et al. (27) used sequential kidney followed
by islet transplantation and the Edmonton protocol. Of 8
patients transplanted, insulin-free status was achieved in
all for at least 3 months, and 5 of 11 were insulin-free after
an average of 24 months (11–34). O’Connell et al. (28)
reported that of six recipients, two were insulin-free at 24
months. Cure et al. (29) reported seven patients who
underwent the islet after kidney transplantation approach;
two achieved insulin-independence and six had persistent
graft function at 1 year. Deng et al. (30) compared islet
transplantation alone (ITA) with islet after kidney (IAK)
transplantation. They observed partial function (C-peptide
positivity) at 24 months in four of eight and six of six
recipients in the ITA and IAK groups, respectively, as well
as insulin-independence at 24 months in four of eight and
ﬁve of six, respectively. These reports from groups in
various parts of the world using more or less the same
Edmonton protocol, some with the added feature of
studying islet after kidney transplantation, generally
achieved similar results reported by the Edmonton and
ITN groups. The overall conclusion of these studies is that
islet transplantation can be considered largely successful
at 1 year with a decline thereafter to an average success
rate (insulin-independence and at least nearly normal
glycemia) of 50% at various times during the 2nd year, and
appreciably less at 5 years post-transplant.
Do persistently measureable C-peptide levels combined
with either a return to less intense insulin therapy and less
hypoglycemia or, alternately, a state of insulin-indepen-
dence but not completely normal A1C levels both repre-
sent successes, partial successes, partial failures, or
failures? These questions are still being debated.
Partial failure or partial success? The analogy of
whether a glass is half full or half empty seems unavoid-
able in an analysis of success versus failure in alloislet
transplantation. The answer to this question is in the eye of
the beholder. To the skeptic’s eye, the procedure looks
interesting, but is replete with problems. Given the current
nearly normal life expectancy of people with type 1
diabetes who are well managed with insulin-based treat-
ment, an invasive procedure with a 50% chance of success
for only 1–2 years does not seem very useful. To the
optimist’s eye, a different conclusion might be reached.
Certain patients with type 1 diabetes are difﬁcult to
manage medically and have a very poor quality of life
because of recurrent hypoglycemia and rapid development
of chronic complications secondary to chronic hypergly-
cemia. The Diabetes Care and Complications Trial (31)
established that maintenance of A1C levels less than or
equal to 7% is mandatory for minimizing complications. A
procedure, such as alloislet transplantation, which shows
promise of providing C-peptide positivity, nearly normal
A1C levels, and strikingly fewer episodes of hypoglyce-
mia for as long as 5 years, cannot be easily dismissed
(24,32–33). Furthermore, initial reports have appeared
claiming that islet recipients have macro- and microvas-
cular as well as quality of life beneﬁts from restoration
of C-peptide secretion even if A1C levels are not nor-
malized (34–36).
An objective approach to evaluating the progress of islet
transplantation is to compare its history to that of pan-
creas transplantation. The procedure of pancreas trans-
plantation, originated at the University of Minnesota,
struggled greatly in its early days with high patient mor-
tality and failure of grafts by 6 months (37). However, a
return to the canine lab to reshape protocols and the
advent of cyclosporine changed things dramatically. In the
ensuing decades, a gratifying increase in pancreas survival
and decrease in patient mortality took place. At its current
zenith of success, pancreas transplantation enjoys virtu-
ally no patient mortality attributable to the surgery and an
average of 80% success 3 years post-transplantation (38).
Plotting success rates as a function of time (Fig. 2), one
sees that islet transplantation might not being doing quite
as poorly as one might at ﬁrst think. Pancreas allograft
survival at 15 months post-transplant in the third epoch of
this procedure (1984–1987) was precisely that of islet
transplantation in its ﬁrst successful years of 2000–2005,
namely, 50%. This is an argument for patience as modiﬁ-
cations of islet transplantation emerge.
A major deﬁciency of virtually all published studies of
islet transplantation is the lack of a suitable control group
of medically managed patients. While one might argue that
islet transplantation improves the health and lives of islet
recipients, this is not the central issue. Such an argument
begs the question of whether the complicated and expen-
sive procedure of islet transplantation performs better
than standard insulin-based therapy. Without a random-
ized, nontransplanted control group, there is very likely a
selection bias in transplanted groups. Patients who choose
islet transplantation do so because they view their quality
of life as poor, most often because of recurrent hypogly-
cemia. It is not always clear from published reports how
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FIG. 2. Comparison of rates of progress of alloislet transplantation
versus pancreas transplantation as therapy for type 1 diabetes. The
ﬁrst alloislet transplant to be reported as successful appeared in 1980,
20 years earlier than the Edmonton series was reported. The ﬁrst
pancreas transplant to be reported as successful appeared in 1966, 18
years earlier than the 1984–1987 series was reported. At 15 months
post-transplant, the Edmonton series of alloislet transplants for the
years 2000–2005 compared favorably with the success rate of pancreas
transplants for the years 1984–1987. Data from refs. 24 and 38.
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made or how vigorously such patients underwent a period
of insulin-based management by skilled diabetologists.
Consequently, one cannot be certain of the claim that
partially failed islet transplantation leads to the use of less
insulin and less hypoglycemia on a cause-effect basis. It
could just as easily be that patients who enter transplant
programs come under close clinical scrutiny by interested
diabetologists who begin managing them more skillfully.
The sole study that did include a medically managed
control group was reported by Thompson et al. (36). In
this study, 44 patients were candidates for islet transplan-
tation; 27 became islet recipients whereas 17 continued on
medical management. The group receiving transplants
were reported to have less likelihood of progression of
retinopathy than the medically managed patients. How-
ever, the results are confounded by two facts. First,
although the two groups had comparable durations of
diabetes, no randomization procedure was used to deter-
mine which patients would be transplanted, and, second,
A1C levels at entry into the study were signiﬁcantly lower
in the transplant group. Nonetheless, this is a valuable
study that illustrates the possibility for randomized stud-
ies to ascertain whether islet transplantation accrues
additional beneﬁts compared with intensive medical
management.
Strategies to top off the half-full glass
Fully evaluate islet function before and after trans-
plantation. With few exceptions, published reports of
islet transplantation in type 1 diabetes have not adequately
assessed the level to which endogenous insulin secretion
is restored by the procedure. In most instances, basal
levels and sometimes glucose-stimulated responses of
C-peptide from recipients post-transplant are provided.
Prior to transplant, only meager laboratory data about
functionality of the islets to be transplanted are generally
obtained. Typically, islets are stimulated with low and high
concentrations of glucose in static incubations, and data
are reported as a “secretory index” (insulin or C-peptide
responses to the higher glucose concentration divided by
the response to the lower glucose concentration). This
practice at best relates only to whether the islets are alive
or dead and imparts little about their degree of function-
ality. Consider, for example, that a fold response (usually
1.0 or a doubling is considered acceptable) to the higher
glucose challenge will be dramatically affected by the
baseline value. The lower the denominator used to divide
the numerator, the more exaggeratedly high the quotient
will look. What is needed is assessment of glucose-induced
insulin secretion by either static or perifusion protocols.
The former uses several glucose concentrations so that a
half-maximal effective concentration can be calculated;
the latter uses multiple samples during perifusion so that
assessment of ﬁrst- and second-phase responses to glucose
stimulation can be obtained. These approaches would pro-
vide much more sophisticated information about the donor
islets used for human transplantation and would go a long
way in interpreting the clinical outcomes obtained in recipi-
ents. The usefulness of more intensive functional studies can
be easily appreciated from the autoislet experience in hu-
mans. In this scenario, the number of islets transplanted
correlates very well with the magnitude of insulin responses
to several stimulii (39).
Improve methods of islet preparation. Reported out-
comes in the current literature have come from programs
that made heroic efforts to procure pancreata as quickly as
possible and then produce islet preparations that were as
pure as possible. This involved exposure of islets to
collagenase for variable periods of time followed by
extensive centrifugation in cold temperatures. As many as
50% of islets are lost during this routine. The 50% that are
recovered after puriﬁcation by cold centrifugation are, not
surprisingly, often damaged. The method of counting
viable islets afterward may or may not include damaged
islets that are not totally dead. It seems very likely that the
number of healthy, transplanted islets is signiﬁcantly over-
estimated, meaning the recipients may not have received
the stated goal of 6,000 healthy islets/kg body mass.
Transplanting 6,000 islets/kg body mass delivers roughly
420,000 islets per person, 40–50% the number of islets in a
pancreas of a nondiabetic human. This number is similar
to that contained in the remaining pancreatic segment in
hemipancreatectomized donors and in the recipient of a
hemipancreas, and is adequate to maintain normoglycemia
for many years (40,41). Yet, the alloislet success rate is on
average only 50% at 15 months. An important difference is
that islets used for autoislet transplantation are not puri-
ﬁed and undergo much less stress pretransplantation. One
answer to the alloislet problem may be to eliminate the
cold centrifugation step (42). Cold centrifugation mini-
mizes the total tissue mass used to infuse islets into the
liver, which is thought to lessen the likelihood of compli-
cations such as hepatic portal hypertension or lobar
infarction. However, this may be a case of too much
caution because autoislet transplantation, in which there
is no puriﬁcation, has no signiﬁcant history of either
complication.
Consider nonhepatic sites for transplantation.
Lacy’s group originally recommended the liver, based on
their rodent studies, and thereafter it was the site tradi-
tionally used for human auto- and alloislet transplantation.
However, not only is the liver the site where ingested
environmental toxins accumulate, but it is also where
orally administered immunosuppressive drugs that are
toxic to -cells are concentrated. Drug concentrations in
hepatic portal venous blood are two- to threefold greater
than in systemic circulation (43,44) and reach concentra-
tions that inhibit -cell function in vitro (3,12–19). This and
other complications of currently available immunosup-
pressive drugs (infection, potential cancer) demand that
the search for less toxic drugs continue unabated so that
the islet, as well as pancreas, transplantation approach can
become more clinically acceptable.
Take full advantage of -cell function in trans-
planted islets. Intrahepatic islets do not have normal
glucagon responses to hypoglycemia (Fig. 3), although
they do respond normally to other stimuli, such as argi-
nine. This has been demonstrated in human autoislet
recipients (45,46), human alloiset recipients (47,48), and
animals (49,50). There are numerous potential reasons for
this defect (51). A likely explanation is that glucose ﬂux
within the liver comes into contact with -cells on the
periphery of transplanted islets. This is especially relevant
during hypoglycemia when glycogenolysis is stimulated by
catecholamines and central nervous system inputs. The
intimate contact between intrahepatic glucose ﬂux and
-cells in the islet allograft abrogates the hypoglycemic
signal delivered to the transplanted -cells from systemic
blood coursing through the hepatic artery. This hypothesis
was tested in animals that received alloislet transplanta-
tion in hepatic and nonhepatic sites and thereafter under-
went insulin-induced hypoglycemic challenges before and
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glucagon responses to hypoglycemia were present. When
the intrahepatically transplanted animals underwent pro-
longed fasts and hepatic glycogen depletion, the initially
absent glucagon responses to hypoglycemia were recov-
ered (Fig. 4). Refeeding the animals to replete liver glyco-
gen caused the glucagon response to hypoglycemia to
disappear once again.
The clinical implications of these data are readily appar-
ent. It is very important to retain -cell responses to
hypoglycemia in humans who undergo islet transplanta-
tion, return to insulin therapy, and become once again at
risk for hypoglycemia. It is established that glucagon
responses to hypoglycemia from the native pancreas of
type 1 diabetic patients is defective because of absent
signaling from neighboring -cells. Alloisets transplanted
in nonhepatic sites will respond to hypoglycemia and will
protect the patient with a partially successful transplant
who uses insulin to manage hyperglycemia. What alternate
sites might be considered? Preclinical literature supports
consideration of celiac artery, intravenous access to
lung, intrapancreas, intramuscular, subcutaneous, thy-
mus, testis, intracisterna magna, omental pouches,
bowel surfaces, peritoneal cavity, spleen, bone marrow,
and kidney capsule (50,52–54). I believe the use of liver
should be reconsidered and a new look should be given
to other sites ﬁrst examined in 1972 but passed over for
human use.
Bridge to the future. A valid argument against islet
transplantation as a treatment for type 1 diabetes is the
undeniable arithmetic that not nearly enough pancreas
donors exist to treat patients with type 1 diabetes, let
alone all people with type 1 and type 2 diabetes, especially
in the face of the current diabetes epidemic. Does this
mean we have been wasting our time and resources by
studying islet transplantation? I don’t believe so. There
will always be diabetic patients who need -cell replace-
ment by transplantation of islets or the pancreas. One
group of patients comprises those with rapid development
of secondary complications despite optimal medical
care. Another group is made up of patients with the
neurological disorder of autonomic insufﬁciency, which
is accompanied by a 50% death rate within 5 years of
diagnosis. They are clearly candidates because success-
ful pancreas transplantation converts this death rate
from 50 to 10%. One must also consider what the future
may bring. Our experiences with islet transplantation
have taught us lessons that will be important for the use
of -cell surrogates, be they stem cell derivatives or
modiﬁed cell lines. We have learned about culturing
cells, isolating islets and -cells, identifying safe and
physiological sites for transplantation, avoiding immu-
nosuppressive drugs that are toxic to -cells, meeting
environmental needs for physiological -cell function,
and selecting appropriate patients for -cell replace-
ment. This is important information to use as we
continue to meet the challenge of creating better means
of controlling hyperglycemia and avoiding its complica-
tions. We just need to continue on with new scientiﬁc
work until the transplantation glass is successfully
ﬁlled.
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